Earnings ·
Sarepta Therapeutics reported second quarter 2026 financial results on August 5, 2026
SRPTSarepta Therapeutics, Inc.
Sarepta Therapeutics reported second quarter 2026 financial results on August 5, 2026. Net product revenues totaled $328.7 million, comprising $230.6 million from PMO therapies and $98.1 million from ELEVIDYS. The company achieved GAAP operating income of $13.3 million and non-GAAP operating income of $86.5 million. Total revenues decreased 34% to $401.3 million, primarily due to lower ELEVIDYS sales volume following an updated label restricting treatment to ambulatory patients and the absence of a prior-year Roche milestone payment. Sarepta narrowed its full-year 2026 revenue guidance to $1.2-$1.3 billion from a previous range of $1.2-$1.4 billion, while reducing combined non-GAAP R&D and SG&A expense guidance to $800.0-$850.0 million. The company also recorded a $39.0 million litigation contingency charge related to patent disputes. Michael Severino, MD, began his tenure as CEO on July 28, 2026, succeeding Doug Ingram. Sarepta Therapeutics operates in the biopharmaceutical industry, specializing in precision genetic medicines for rare diseases.